LY4395089

LY4395089 is an investigational, oral small molecule agonist of the **farnesoid X receptor (FXR)**, currently under development by **Eli Lilly and Company** for the treatment of **Crohn's disease**. FXR is a nuclear receptor primarily expressed in the liver and intestine that regulates bile acid synthesis, transport, and metabolism. In the context of inflammatory bowel disease (IBD), FXR activation has been shown to exert anti-inflammatory effects, maintain intestinal barrier integrity, and modulate the gut microbiota. LY4395089 is being evaluated in Phase 2 clinical trials to assess its safety and efficacy, particularly when co-administered with the IL-23p19 antagonist mirikizumab (Omvoh), to explore whether targeting both the FXR pathway and the IL-23 cytokine pathway provides enhanced therapeutic benefit for patients with moderately to severely active Crohn's disease.